Search

Your search keyword '"Cell Therapeutics Inc. -- Licensing agreements"' showing total 38 results
Start Over Descriptor "Cell Therapeutics Inc. -- Licensing agreements"
38 results on '"Cell Therapeutics Inc. -- Licensing agreements"'

1. Eterna inks option and license agreement with Lineage Cell Therapeutics to develop iPSC lines for multiple neurology indications

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Intellectual property, Stem cells -- Transplantation, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Intellectual property, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

Eterna Therapeutics Inc., a preclinical-stage biotechnology company announced that it has entered into an exclusive option and license agreement (the 'Agreement') with Lineage Cell Therapeutics, Inc. (Lineage) for the development [...]

Published
2023

2. Lineage inks collaboration with Genentech to develop & commercialize OpRegen RPE cell therapy to treat ocular disorders

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Roche Holding AG -- Licensing agreements, Biological products industry -- Licensing agreements, Medical research, Medicine, Experimental, Printing-ink -- Licensing agreements, Eye diseases, Biotechnology industry -- Licensing agreements, Macular degeneration, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

Lineage Cell Therapeutics, Inc. announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and license agreement with Roche and Genentech, a member [...]

Published
2021

3. Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Stem cells, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

CARLSBAD: LINEAGE CELL THERAPEUTICS, INC has issued the following news release: Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to replace [...]

Published
2023

4. Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Subjects
United States. Securities and Exchange Commission, Cell Therapeutics Inc. -- Licensing agreements, Stem cells, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

CARLSBAD, Calif. -- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to replace and restore specific cell types of the human [...]

Published
2023

5. Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Stem cells -- Transplantation, RNA, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

CAMBRIDGE, Mass: Eterna Therapeutics has issued the following news release: Eterna Therapeutics Inc. (Nasdaq: ERNA) ('Eterna'), a preclinical-stage biotechnology company committed to realizing the potential of mRNA cell engineering to [...]

Published
2023

6. BrainStorm Cell Therapeutics to Present at Biotech Showcase(TM) 2023

Subjects
United States. Food and Drug Administration, Cell Therapeutics Inc. -- Licensing agreements, Stem cells, Biotechnology, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

NEW YORK, Jan. 5, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Chaim Lebovits, President [...]

Published
2023

7. Lineage Enters Into Option and License Agreement with Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Stem cells -- Transplantation, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-February 24, 2023-Lineage Enters Into Option and License Agreement with Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications (C)2023 M2 COMMUNICATIONS - US-based biotechnology company [...]

Published
2023

8. Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen[R] RPE Cell Therapy for the Treatment of Ocular Disorders

Subjects
United States. Securities and Exchange Commission, Cell Therapeutics Inc. -- Licensing agreements, Roche Holding AG -- Licensing agreements, Biological products industry -- Licensing agreements, Eye diseases, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

* Genentech Will Pay Lineage $50 Million Upfront * Eligible to Receive a Total of $670 Million in Upfront and Milestone Payments * Conference Call to Discuss Collaboration Planned for [...]

Published
2021

9. Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Immunotherapy, Cancer -- Care and treatment, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

ROCKVILLE, Md. & CARLSBAD, Calif.: Immunomic Therapeutics, Inc has issued the following news release: Immunomic Therapeutics, Inc., ('ITI'), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid [...]

Published
2021

10. Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Immunotherapy, Antigens, Cancer -- Care and treatment, Cancer vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

Partnership Leverages Lineage's Investigational VAC Allogeneic Cancer Vaccine Platform and Immunomic's Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate ROCKVILLE, Md. & CARLSBAD, Calif. -- Immunomic Therapeutics, [...]

Published
2021

11. Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform

Subjects
United States. Securities and Exchange Commission, Cell Therapeutics Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Immunotherapy, Antigens, Cancer -- Care and treatment, Cancer vaccines -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

* Lineage to Receive $2 Million Upfront and up to $67 Million in Development and Commercial Milestones Plus Royalties * Partnership Leverages the VAC Allogeneic Cancer Immunotherapy Vaccine Platform and [...]

Published
2021

12. Lineage Enters Into Exclusive Agreement with Neurgain Technologies to Evaluate Novel Delivery System for OPC1 to Treat Spinal Cord Injury

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Spinal cord injuries -- Care and treatment, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

CARLSBAD: Lineage Cell Therapeutics, Inc. has issued the following news release: Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet [...]

Published
2021

13. Lineage Enters Into Exclusive Agreement with Neurgain Technologies to Evaluate Novel Delivery System for OPC1 to Treat Spinal Cord Injury

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Spinal cord injuries -- Care and treatment, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international, Law
Abstract

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has entered into an exclusive [...]

Published
2021

14. Lineage Enters Into Exclusive Agreement with Neurgain Technologies to Evaluate Novel Delivery System for OPC1 to Treat Spinal Cord Injury

Subjects
United States. Securities and Exchange Commission, Cell Therapeutics Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Spinal cord injuries -- Care and treatment, Company licensing agreement, Business, Business, international
Abstract

- Use of the Neurgain PDI system could support later-stage trials of OPC1 in cervical injury patients - OPC1 Investor & Analyst Day planned for February 22, 2021 CARLSBAD, Calif. [...]

Published
2021

15. LINEAGE & GENENTECH PARTNER ON RPE CELL THERAPY

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Roche Holding AG -- Licensing agreements, Biological products industry -- Licensing agreements, Medical research, Medicine, Experimental, Eye diseases, Biotechnology industry -- Licensing agreements, Macular degeneration, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Biotechnology industry, Business
Abstract

Lineage Cell Therapeutics, Inc. and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and license agreement with Roche and Genentech, a member of the Roche [...]

Published
2022

16. Lineage Establishes Exclusive Worldwide Collaboration with Genentech for the Development and Commercialization of OpRegen RPE Cell Therapy for the Treatment of Ocular Disorders

Subjects
Genentech Inc. -- Licensing agreements, Cell Therapeutics Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Eye diseases, Biotechnology industry -- Licensing agreements, Macular degeneration, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-December 20, 2021-Lineage Establishes Exclusive Worldwide Collaboration with Genentech for the Development and Commercialization of OpRegen RPE Cell Therapy for the Treatment of Ocular Disorders (C)2021 M2 COMMUNICATIONS - [...]

Published
2021

17. Immunomic Therapeutics Announces License Agreement with Lineage Cell Therapeutics for Cancer Immunotherapy

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Gliomas, Immunotherapy, Antigens, Cancer -- Care and treatment, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-April 21, 2021-Immunomic Therapeutics Announces License Agreement with Lineage Cell Therapeutics for Cancer Immunotherapy (C)2021 M2 COMMUNICATIONS - US-based biotechnology company Immunomic Therapeutics, Inc has inked a worldwide license [...]

Published
2021

18. Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Intellectual property, Pharmaceutical industry -- Licensing agreements, Cash transactions, Biotechnology industries, Novels, Intellectual property, Company licensing agreement, General interest, News, opinion and commentary
Abstract

CARLSBAD: Lineage Cell Therapeutics, Inc. has issued the following news release: -Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet [...]

Published
2019

19. Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Intellectual property, Pharmaceutical industry -- Licensing agreements, Cash transactions, Technology, Biotechnology industries, Novels, Intellectual property, Company licensing agreement, Business, international, Law
Abstract

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today announced that it has entered into license agreements [...]

Published
2019

20. Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets

Subjects
United States. Securities and Exchange Commission, Cell Therapeutics Inc. -- Licensing agreements, Intellectual property, Biotechnology industries -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Cash transactions, Technology, Novels, Intellectual property, Company licensing agreement, Business, Business, international
Abstract

CARLSBAD, Calif. -- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today announced that it has entered [...]

Published
2019

21. Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Intellectual property, Pharmaceutical industry -- Licensing agreements, Cash transactions, Biotechnology industries, Intellectual property, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-December 24, 2019-Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets (C)2019 M2 COMMUNICATIONS - US-based clinical-stage biotechnology company Lineage Cell Therapeutics, Inc. [...]

Published
2019

22. NEW DRUG APPROVALS OF 2000--Part 1

Author

Davis, W. Marvin and Vinson, Michael C.

Subjects
Encysive Pharmaceuticals Inc. -- Licensing agreements, SmithKline Beecham Corp. -- Licensing agreements, Cell Therapeutics Inc. -- Licensing agreements, Salix Pharmaceuticals -- Licensing agreements, Asta Medica -- Licensing agreements, United States. Food and Drug Administration -- Powers and duties, Pharmaceutical industry -- Licensing agreements
Abstract

TRENDS IN PHARMACY AND PHARMACEUTICAL CARE Objectives: Upon completion of this article, the pharmacist should be able to describe for the new molecular entities approved in 2000: [check] Therapeutic use [...]

Published
2001

23. CELL THERAPEUTICS Inc

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Leukemia -- Drug therapy, Business, Chemicals, plastics and rubber industries, Trisenox (Medication) -- Marketing
Abstract

CELL THERAPEUTICS Inc. has received FDA approval for Trisenox (arsenic trioxide) to treat acute promyelocytic [...]

Published
2000

24. Cell Therapeutics seeks OK for leukemia drug

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Cell Therapeutics Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Business, Business, regional
Abstract

Cell Therapeutics Inc. of Seattle said it has filed a new drug application with the Food and Drug Administration for approval of arsenic trioxide as a treatment for one type [...]

Published
2000

25. Novartis gets cancer licence

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Chemicals, plastics and rubber industries
Abstract

(From Chemical Business NewsBase - Chemical and Engineering News) Cell Therapeutics Inc and Novartis have concluded a licensing deal under which Novartis will develop and commercialize CTI's Xyotax, which is [...]

Published
2006

26. Cell Therapeutics Inc. Announces Worldwide License and Co-Development Agreement for Development and Commercialization of XYOTAX(TM), an Investigational Agent for Treatment of Women with Non-small Cell Lung Cancer and Other Cancers

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Deal Worth Up to $285 million Can Help Fuel Future Growth at CTI SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced an exclusive [...]

Published
2006

27. Cell Therapeutics, Inc. (CTI)

Subjects
Novartis AG -- Product development, Novartis AG -- Licensing agreements, Cell Therapeutics Inc. -- Licensing agreements, Cell Therapeutics Inc. -- Product development, Paclitaxel -- Product development, Pharmaceutical industry -- Licensing agreements, Pharmaceutical industry -- Product development, Company licensing agreement, Health care industry, Pharmaceuticals and cosmetics industries, Xyotax (Medication) -- Product development
Abstract

Cell Therapeutics, Inc. (CTI) has announced an exclusive worldwide licensing agreement with Novartis for the development and commercialization of an investigational cancer treatment. The deal concerning Xyotax (poliglumex paclitaxel), currently [...]

Published
2006

28. Cell Therapeutics

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Business, Chemicals, plastics and rubber industries
Abstract

CELL THERAPEUTICS has licensed the patent and other intellectual property rights to DiaKine Therapeutics Inc.'s lisofylline, a novel small-molecule anti-inflammatory compound that is being developed for diabetes [...]

Published
2005

29. Cell Therapeutics, Inc. Enters Into Licensing Agreement for PG-TXL With Chugai Pharmaceutical Co., Ltd

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Chugai Pharmaceutical Company Ltd. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Business, News, opinion and commentary
Abstract

Agreement Accelerates Development and Marketing of PG-TXL in the Asian Markets SEATTLE, Oct. 22 /PRNewswire/ -- CTI Technologies, Inc. (CTIT), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC), [...]

Published
2001

30. Cell Therapeutics, Chroma Therapeutics sign co-development, licence agreement

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-March 14, 2011-Cell Therapeutics, Chroma Therapeutics sign co-development, licence agreement(C)2011 M2 COMMUNICATIONS 14 March 2011 - US-based company Cell Therapeutics Inc (CTI) (NASDAQ: CTIC) and Chroma Therapeutics Ltd (Chroma) [...]

Published
2011

31. Cell Therapeutics announces licensing agreement with Novartis for Xyotax in treating NSCLC

Subjects
Novartis AG -- Licensing agreements, Cell Therapeutics Inc. -- Licensing agreements, Drugs -- Licensing agreements, Cancer -- Care and treatment, Lung cancer, Non-small cell, Pharmaceutical industry -- Licensing agreements, Health, Science and technology, Company licensing agreement, Licensing agreements
Abstract

Cell Therapeutics, Inc. (CTI) (CTIC) announced an exclusive worldwide licensing agreement with Novartis for the development and commercialization of Xyotax (poliglumex paclitaxel), an investigational agent in Phase III for the [...]

Published
2006

32. Cell Therapeutics announces licensing agreement with Novartis for Xyotax in treating NSCLC

Subjects
Novartis AG -- Licensing agreements, Cell Therapeutics Inc. -- Licensing agreements, Xyotax (Medication), Drugs -- Licensing agreements, Cancer -- Care and treatment, Lung cancer, Non-small cell, Pharmaceutical industry -- Licensing agreements, Health, Company licensing agreement, Licensing agreements
Abstract

Cell Therapeutics, Inc. (CTI) (CTIC) announced an exclusive worldwide licensing agreement with Novartis for the development and commercialization of Xyotax (poliglumex paclitaxel), an investigational agent in Phase III for the [...]

Published
2006

33. Cell Therapeutics announces licensing agreement with Novartis for Xyotax in treating NSCLC

Subjects
Company licensing agreement, Xyotax (Medication) -- Licensing agreements, Drugs -- Licensing agreements, Cancer -- Care and treatment, Lung cancer, Non-small cell, Pharmaceutical industry -- Licensing agreements, Novartis AG -- Licensing agreements, Cell Therapeutics Inc. -- Licensing agreements
Abstract

Cell Therapeutics, Inc. (CTI) (CTIC) announced an exclusive worldwide licensing agreement with Novartis for the development and commercialization of Xyotax (poliglumex paclitaxel), an investigational agent in Phase III for the [...]

Published
2006

34. License agreement for platinum-containing, anticancer drug candidates

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Cytology, Antineoplastic agents -- Licensing agreements, Cancer -- Care and treatment, Pharmaceutical industry -- Licensing agreements, Antimitotic agents -- Licensing agreements, Health, Science and technology, Company licensing agreement, Licensing agreements
Abstract

The University of Vermont, and Cell Therapeutics Europe S.r.l., a subsidiary of Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC), have entered into an exclusive worldwide, royalty-bearing license to a new class of [...]

Published
2005

35. License agreement for platinum-containing, anticancer drug candidates

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Roche Holding AG -- Licensing agreements, Licensing agreements, Company licensing agreement, Cancer treatment, Pharmaceutical industry -- Licensing agreements, Antineoplastic agents -- Licensing agreements, Cytology, Cancer -- Care and treatment, Antimitotic agents -- Licensing agreements
Abstract

The University of Vermont, and Cell Therapeutics Europe S.r.l., a subsidiary of Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC), have entered into an exclusive worldwide, royalty-bearing license to a new class of [...]

Published
2005

36. License agreement for platinum-containing, anticancer drug candidates

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Roche Holding AG -- Licensing agreements, Licensing agreements, Company licensing agreement, Cancer treatment, Pharmaceutical industry -- Licensing agreements, Antineoplastic agents -- Licensing agreements, Cytology, Cancer -- Care and treatment, Antimitotic agents -- Licensing agreements
Abstract

The University of Vermont, and Cell Therapeutics Europe S.r.l., a subsidiary of Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC), have entered into an exclusive worldwide, royalty-bearing license to a new class of [...]

Published
2005

37. Cell Thera's Lisofylline licensed to DiaKine

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

Cell Therapeutics has signed a deal with fellow USA-based group DiaKine Therapeutics, under which the latter obtains the patent and other intellectual property rights related to the former's lisofylline for [...]

Published
2005

38. Cell Therapeutics Signs Licensing Agreement For PG-TXL With Chugai

Subjects
CTI Technologies Inc. -- Licensing agreements, Cell Therapeutics Inc. -- Licensing agreements, Chugai Pharmaceutical Company Ltd. -- Licensing agreements, Cancer
Abstract

2001 NOV 20 - (NewsRx.com & NewsRx.net) -- CTI Technologies, Inc., (CTIT) a wholly owned subsidiary of Cell Therapeutics, Inc., (CTIC) has entered into a licensing agreement with Chugai Pharmaceutical [...]

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results